IMPORTANT: Beginning at 8:00 AM on July 22, Temple University Hospital – Main Campus (Broad and Ontario Streets) will no longer provide Labor and Delivery services. All childbirth services will be relocated to our new hospital location.

800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILLAR)

view all Clinical Trials

Overview

The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.

Contact

For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.